COMP360 Shows Durable 52-Week Efficacy in Phase 3 COMP005; Stock Jumps 11%
CMPS has more than doubled off its 52-week low of $4.82.
Summary
Compass Pathways released 52-week Part C data from its Phase 3 COMP005 trial of COMP360 in treatment-resistant depression. The open-label extension showed a 13-point MADRS reduction in the 25 mg arm and a 10-point reduction in placebo crossovers, with 40-45% response and ~30% remission rates. No new safety signals. The stock rose over 11% on the news. This follows the positive 26-week COMP006 data from July and supports the rolling NDA submission, expected to complete in Q4 2026, with a potential launch in H1 2027. The durability data strengthens the commercial case for COMP360 and de-risks the regulatory path.
At the time of this announcement, CMPS was trading at $15.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $4.82 to $15.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.